AdvanCell has raised an oversubscribed $315 million Series D to fund development of its lead radiopharmaceutical candidate ADVC-001 and to expand isotope supply and manufacturing infrastructure. The round supports late-stage clinical development and positions the company as it moves deeper into prostate-specific membrane antigen (PSMA)-targeted radioligand testing for metastatic castration-resistant prostate cancer.